Table 2 –
Total complications avoided in the UK T2DM population estimated from the Baxter et al. [13] study and by participating modeling groups.
| Complications | Baxter study | Participating modeling groups | |||
|---|---|---|---|---|---|
| Cardiff model | ECHO-T2DM | MDM-TTM | IQVIA-CDM | ||
| Eye disease | |||||
| 5 y | 56,777 | 12,046 | 403,839 | 5,045 | 19,530 |
| 10 y | 141,792 | 19,764 | 684,490 | 15,825 | 129,321 |
| 15 y | 224,992 | 26,477 | 837,948 | 27,536 | 269,037 |
| 20 y | 261,069 | 31,865 | 898,574 | 34,382 | 399,513 |
| 25 y | 250,768 | 34,701 | 942,337 | 36,514 | 456,766 |
| Renal disease | |||||
| 5 y | 38,151 | 25 | 14,712 | 1,652 | 13,489 |
| 10 y | 95,975 | 40 | 26,794 | 3,724 | 77,000 |
| 15 y | 152,114 | 47 | 35,785 | −1,982 | 164,851 |
| 20 y | 174,601 | 52 | 41,835 | −14,083 | 255,038 |
| 25 y | 164,187 | 59 | 47,992 | −27,836 | 294,751 |
| Foot ulcers, amputations, and neuropathy | |||||
| 5y | 122,013 | 15,847 | 78,367 | 3,934 | 9,343 |
| 10 y | 275,011 | 27,678 | 163,711 | 15,975 | 162,908 |
| 15 y | 389,723 | 35,548 | 229,138 | 33,422 | 286,712 |
| 20 y | 412,535 | 43,458 | 265,308 | 47,265 | 354,630 |
| 25 y | 373,629 | 49,324 | 292,704 | 54,802 | 347,470 |
| Cardiovascular disease | |||||
| 5y | 27,991 | 23,124 | 46,472 | 13,303 | 5,569 |
| 10 y | 61,893 | 50,804 | 97,207 | 40,358 | 40,431 |
| 15 y | 97,890 | 115,335 | 132,514 | 64,231 | 91,852 |
| 20 y | 106,416 | 92,475 | 147,792 | 73,479 | 146,743 |
| 25 y | 82,387 | 112,709 | 149,673 | 68,224 | 168,866 |
ECHO, Economics and Health Outcomes Model of T2DM; MDM-TTM, Medical Decision Modeling Inc.—Treatment Transitions Model; IQVIA-CDM, IQVIA-CORE Diabetes Model; T2DM, type 2 diabetes mellitus.